AL001 for Frontotemporal Dementia in Healthy Volunteers and People with FTD
Start: September 14, 2018
End: December 31, 2019
Enrollment: 60
What Is This Study About?
This Phase 1 study is testing the investigational drug AL001 as a possible treatment for frontotemporal dementia (FTD) in healthy volunteers and people with FTD who also have a granulin mutation (PGRN).
Do I Qualify To Participate in This Study?
Minimum Age: 18 Years
Maximum Age: 80 Years
Must have:
- BMI 18 to 35
- Weight 99 to 265 lbs
- Not pregnant or lactating
- Females of childbearing potential must agree to use adequate contraception from screening until 90 days after the follow-up visit
- No significant findings on medical history, physical exam, laboratory tests, electrocardiogram, or other tests
Must NOT have:
- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to antibodies or fusion proteins
- Positive drug or alcohol at screening and prior to first dose
- History of alcohol or substance abuse
If I Qualify, Who Do I Contact?
Contact study personnel listed either under the general study contact or the location nearest you.
Study Contact
Study Lead
Need Help?
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Where Is This Study Located?
Who Sponsors This Study?
Lead: Alector Inc.
Source: ClinicalTrials.gov ID: NCT03636204